March 22nd 2023
Patients with metastatic or recurrent locally advanced Merkel cell carcinoma can now receive treatment with retifanlimab-dlwr following its accelerated approval by the FDA.
Rheumatic Adverse Events Reported for Patients Treated with Nivolumab, IpilimumabJune 22nd 2016
Inflammatory arthritis and sicca syndrome appear to be immune-related adverse events among some patients undergoing cancer treatment with the immune checkpoint inhibitors nivolumab and ipilimumab.
Dr. Giulio Draetta Talks About the Moon Shots Program at MD AndersonFebruary 26th 2016
In light of the recent announcement by Vice President Joe Biden to infuse the US cancer research program with $1 billion, a so-called “Moon Shot” program, we are speaking today with Giulio Draetta, a clinician and cancer researcher at MD Anderson Cancer Center at the University of Texas in Houston, who leads that center’s Moon Shots program.